

Appl. No. 09/993,300 Amdt. dated Reply to Office action of June 14, 2005

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (currently amended) An isolated biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1 ~~[[and]] or~~ consisting of SEQ ID NO:2.

Claims 2-38. (cancelled).

Insert
Claim ²~~39~~. (withdrawn-currently amended) A method for determining ^{in a patient sample} ~~the~~ presence of ~~a~~ ^{which is linked to Type II diabetes} ~~an isolated biopolymer marker~~ selected from the group consisting of SEQ ID NO:1 ~~[[and]] or~~ consisting of SEQ ID NO:2 ^{comprising:}

(a) obtaining a sample from a patient;

(b) conducting mass spectrometric analysis on said sample in a manner effective to maximize analysis of peptide fragments contained therein and comparing mass spectrum profiles of said isolated biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1 ~~[[and]] or~~ consisting of SEQ ID NO:2 to mass spectrum profiles of peptides obtained and analyzed from said sample; and

Appl. No. 09/993,300 Amdt. dated Reply to Office action of June 14, 2005

(c) confirming the presence of said ~~isolated~~ biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1 ~~[[and]]~~ ~~or consisting of~~ SEQ ID NO:2 in said sample displaying a peak profile at about 1624 daltons or at about 1552 daltons in said mass spectrum profile;

wherein the presence of said ~~isolated~~ biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1 ~~[[and]]~~ ~~or consisting of~~ SEQ ID NO:2 is indicative of a link to Type II diabetes.

Claim ³40. (withdrawn) The method of claim ²39, wherein said sample is an unfractionated body fluid or tissue sample.

Claim ⁴41. (withdrawn) The method of claim ³39, wherein said sample is selected from the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.

Claim ⁵42. (withdrawn) The method of claim ²39, wherein said mass spectrometric analysis is selected from the group consisting of Surface Enhanced Laser Desorption Ionization (SELDI) mass spectrometry (MS), Maldi Qq TOF, MS/MS, TOF-TOF, ESI-Q-TOF and ION-TRAP.

Appl. No. 09/993,300 Amdt. dated Reply to Office action of June 14, 2005 2

Claim 43.6 (withdrawn) The method of claim 39, wherein said patient is a human.

Claim 44.7 (withdrawn-currently amended) A kit for determining the presence of a ~~an~~ isolated biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1 ~~[[and]]~~ or consisting of SEQ ID NO:2 comprising: (a) a ~~an~~ isolated biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1 ~~[[and]]~~ or consisting of SEQ ID NO:2, and (b) an antibody that binds to said ~~isolated~~ biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1 ~~[[and]]~~ or consisting of SEQ ID NO:2 in a sample from a patient.

Claim 45.8 (withdrawn) The kit of claim 44, wherein said antibody is immobilized on a solid support.

Claim 46.9 (withdrawn) The kit of claim 44, wherein said antibody is labeled.